A Randomized, Double-Blind, Placebo-Controlled Phase 2 Clinical Trial Comparing CB-839 in Combination With Cabozantinib (CB-Cabo) vs. Placebo With Cabozantinib (Pbo-Cabo) in Patients With Advanced or Metastatic Renal Cell Carcinoma (RCC)
A Randomized, Double-Blind, Placebo-Controlled Phase 2 Clinical Trial Comparing CB-839 in Combination With Cabozantinib (CB-Cabo) vs. Placebo With Cabozantinib (Pbo-Cabo) in Patients With Advanced or Metastatic Renal Cell Carcinoma (RCC)
Tthe primary objective of this study is to compare blinded Independent Radiology Committee (IRC)-adjudicated progression free survival (PFS) of patients treated with CB-839 + cabozantinib (CB-Cabo) versus placebo + cabozantinib (Pbo-Cabo) for advanced or metastatic clear-cell RCC (ccRCC).
Inclusion Criteria:
Exclusion Criteria:
Los Angeles, California 90048, United States
Tampa, Florida 33612, United States
Baltimore, Maryland 21201, United States
East Setauket, New York 11733, United States
Pittsburgh, Pennsylvania 15232, United States
Heidelberg, Baden-Wurttemberg 69120, Germany
Dresden, 01307, Germany
Milan, 20141, Italy
Modena, 41124, Italy
Nottingham, Nottinghamshire NG5 1PB, United Kingdom